ImmunityBio stock steadies near $7 after 15% jump; earnings next up
ImmunityBio shares held steady at $6.93 in premarket trading Tuesday after a 14.6% surge Monday. The stock’s rally follows preliminary 2025 net product revenue of about $113 million, up roughly 700% year-over-year. Investors await quarterly results due March 2.